Resources
The National Pharmaceutical Council (NPC) is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation.
Filter by:
Topic
Topic
- Accountable Care Organizations
- Alternative Payment Models
- (-) Biopharmaceutical Innovation
- Bundled Payments
- (-) Clinical Pathways
- Decision Frameworks
- Elements of Value
- Evidence for Decision Making
- Formulary/Benefit Design
- Formulary Development
- Good Practices for Evidence
- Health Care Quality Measures
- Health Spending
- Health Spend Management
- High-Deductible Health Plans
- Impact on Outcome & Spending
- Individual Treatment Effects & Personalized Access
- IRA Implementation
- Low-Value Care
- Pandemic Response
- Patient Cost Sharing
- Paying for Cures
- Policy & Regulatory Barriers
- Real-World Data
- Real-World Evidence
- Regulatory Barriers & Challenges
- (-) Understanding Health Spending
- Utilization Management & Step Therapy
- Value-Based Contracts
- Value-Based Insurance Design
- Value Assessment
- Value Assessment Frameworks
- Value Assessment Methods
Resource Type
Audience
Display Only
Showing 80 Results
What Might Have Happened: The Impact of Interrupting Entry of Innovative Drugs on Disease Outcomes in the United States
A new NPC study shows how major drug innovations significantly improved patient health outcomes for six diseases with substantial mortality or morbidity.
What If Groundbreaking Medicines Never Existed?
New research from estimates what health gains might have been lost without the introduction of influential innovations for six serious diseases.
The Certainty of Uncertainty in Health Technology Assessment
A new Health Affairs Forefront article from Tufts CEVR examines the potential flaws in how health technology assessments identify and report on uncertainty.
How Reforms Can Enable Payment Innovation That Drives Value
This NPC study models the effects of recent and proposed payment reforms related to CMS' best price reporting rules and sheds light on which approaches may encourage the adoption of value-based…
NPC in RealClearPolicy: Price Setting Bill Is No Panacea for Patients
In a commentary for RealClearPolicy, NPC’s John M. O’Brien explains how the drug pricing deal in the Build Back Better Act could create harmful unintended consequences for patient health and the…
Health Spending for Commercial Plans Is Predominantly Concentrated In Small Population of High-Intensity Consumers
NPC study finds spending on prescription drugs mirrors spending on other health care services, with a small subset of the sickest patients driving the majority of spending.
Drug Spending Mirrors Spending on Other Health Care Services
Spending on prescription drugs is not an anomaly but rather follows similar patterns as other health care services. Policy proposals that focus narrowly on constraining drug spending are…
At the Heart of It: How Innovation Drives Improved Patient Outcomes
In honor of World Heart Day, NPC looks at how innovative medical interventions have vastly improved cardiovascular disease outcomes.
A Healthier Country Means Lower Health Care Spending
The U.S. spends twice as much per person on health care compared to other wealthy countries. While higher U.S. health care prices play a role in this disparity, they are not the only cause. A new NPC…
It Is Not Just the Prices! The Role of Chronic Disease in Accounting for Higher Health Care Spending in the United States
A new NPC study shows that the higher prevalence of chronic disease in the U.S. is a significant contributing factor to high U.S. health care spending.
Working Together to Deliver Innovation for Patients During COVID-19 and Beyond
What's at risk if we limit innovation? Read the commentary from NPC's John O'Brien in Chain Drug Review.
Building a Better Evidence Base to Address the Social Determinants of Health
The COVID-19 pandemic has put a spotlight on the pressing need to address social determinants of health (SDOH). NPC's Dr. Dubois examines the gaps within the existing evidence base and how…
Do Investments in the Social Determinants of Health Reduce Health Care Costs?
This study found that most studies of social need interventions were poorly designed, inadequately documented, and inconsistently presented. It recommends improving the study design quality through…
On World Hepatitis Day, Looking at Innovation That Goes Beyond a Pill
Michael Ciarametaro, Vice President of Research at NPC, reflects on how the scientific revolution of hepatitis C led to a corresponding reimbursement revolution that became a fertile ground for large…
What the Data Are Saying on Drug Pricing and Utilization
NPC President and CEO John O'Brien discusses the IQVIA Institute’s new report and takes a closer look at the factors that are driving medication use and health care spending in the United States.
The Trade-off for Price Controls: Are We Willing to Accept Fewer Medicines?
It's possible to strike a balance between innovation and efficient spending, and to implement policies ensuring that resources are being invested in treatments, procedures and public health efforts…
Health Budgets Should Cap Patient Harm
An NPC-RTI study provides guidance on quality metrics and practices that can help decision makers understand which budget cap features have the potential to lessen the impact on patient health and…
AMCP Partnership Forum: Preparing for and Managing Rare Diseases
Stakeholders met virtually for an AMCP Partnership Forum to discuss viable solutions to challenges facing people living with rare disorders, such as affordable and timely access to therapies,…
The Dollar or Disease Burden: Caps on Healthcare Spending May Save Money, but at What “Cost” to Patients?
This study assessed the potential effects of budget caps design on disease burden and cost savings to help budget decision makers understand which budget cap features minimize impact to patient…
Considering the Future Impact of COVID on Health Spending
AcademyHealth and the National Pharmaceutical Council hosted a salon examining the impact of the pandemic on health spending and resulting challenges to our health care system.